Advanced glycation end products and the kidney

被引:301
|
作者
Bohlender, JM [1 ]
Franke, S [1 ]
Stein, G [1 ]
Wolf, G [1 ]
机构
[1] Univ Klin Jena, Innere Med Klin 3, Dept Internal Med 3, Jena, Germany
关键词
RAGE; diabetic nephropathy; progression of renal disease; inflammation; glycoxidation;
D O I
10.1152/ajprenal.00398.2004
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Advanced glycation end products (AGEs) are a heterogeneous group of protein and lipids to which sugar residues are covalently bound. AGE formation is increased in situations with hyperglycemia ( e. g., diabetes mellitus) and is also stimulated by oxidative stress, for example in uremia. It appears that activation of the renin-angiotensin system may contribute to AGE formation through various mechanisms. Although AGEs could nonspecifically bind to basement membranes and modify their properties, they also induce specific cellular responses including the release of profibrogenic and proinflammatory cytokines by interacting with the receptor for AGE ( RAGE). However, additional receptors could bind AGEs, adding to the complexity of this system. The kidney is both: culprit and target of AGEs. A decrease in renal function increases circulating AGE concentrations by reduced clearance as well as increased formation. On the other hand, AGEs are involved in the structural changes of progressive nephropathies such as glomerulosclerosis, interstitial fibrosis, and tubular atrophy. These effects are most prominent in diabetic nephropathy, but they also contribute to renal pathophysiology in other nondiabetic renal diseases. Interference with AGE formation has therapeutic potential for preventing the progression of chronic renal diseases, as shown from data of animal experiments and, more recently, the first clinical trials.
引用
收藏
页码:F645 / F659
页数:15
相关论文
共 50 条
  • [21] Endogenous Secretory Receptor for Advanced Glycation End Products and Chronic Kidney Disease in the Elderly Population
    Dalal, Mansi
    Semba, Richard D.
    Sun, Kai
    Crasto, Candace
    Varadhan, Ravi
    Bandinelli, Stefania
    Fink, Jeffrey C.
    Guralnik, Jack M.
    Ferrucci, Luigi
    AMERICAN JOURNAL OF NEPHROLOGY, 2011, 33 (04) : 313 - 318
  • [22] Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease
    Yabuuchi, Junko
    Ueda, Seiji
    Yamagishi, Sho-ichi
    Nohara, Nao
    Nagasawa, Hajime
    Wakabayashi, Keiichi
    Matsui, Takanori
    Yuichiro, Higashimoto
    Kadoguchi, Tomoyasu
    Otsuka, Tomoyuki
    Gohda, Tomohito
    Suzuki, Yusuke
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] Significance of proximal ribular metabolism of advanced glycation end products in kidney diseases
    Saito, A
    Takeda, T
    Sato, K
    Hama, H
    Tanuma, A
    Kaseda, R
    Suzuki, Y
    Gejyo, F
    MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE, 2005, 1043 : 637 - 643
  • [24] Receptor for Advanced Glycation End Products Antagonism Blunts Kidney Damage in Transgenic Townes Sickle Mice
    Charrin, Emmanuelle
    Faes, Camille
    Sotiaux, Amandine
    Skinner, Sarah
    Pialoux, Vincent
    Joly, Philippe
    Connes, Philippe
    Martin, Cyril
    FRONTIERS IN PHYSIOLOGY, 2019, 10
  • [25] Advanced glycation end products, oxidative stress and diabetic nephropathy
    Yamagishi, Sho-ichi
    Matsui, Takanori
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2010, 3 (02) : 101 - 108
  • [26] Clinical/Translational Aspects of Advanced Glycation End-Products
    Zeng, Chang
    Li, Yuanyuan
    Ma, Jingzhi
    Niu, Lina
    Tay, Franklin R.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2019, 30 (12) : 959 - 973
  • [27] Advanced Glycation End Products: key player of the pathogenesis of atherosclerosis
    Singh, Sanjiv
    Siva, Boddu Veerabadra
    Ravichandiran, V.
    GLYCOCONJUGATE JOURNAL, 2022, 39 (04) : 547 - 563
  • [28] THE ROLE OF ADVANCED GLYCATION END PRODUCTS IN PATOGENESIS OF DIABETIC NEPHROPATHY
    Gavrilova, Alina O.
    Severina, Anastasia S.
    Shamhalova, Minara S.
    Shestakova, Marina, V
    DIABETES MELLITUS, 2021, 24 (05): : 461 - 469
  • [29] Advanced glycation end products (AGEs) activate mast cells
    Sick, E.
    Brehin, S.
    Andre, P.
    Coupin, G.
    Landry, Y.
    Takeda, K.
    Gies, J. P.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 161 (02) : 442 - 455
  • [30] Advanced glycation end products (AGEs) and their involvement in liver disease
    Hyogo, Hideyuki
    Yamagishi, Sho-ichi
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) : 969 - 972